These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

459 related items for PubMed ID: 1412169

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. R 68 070: thromboxane A2 synthetase inhibition and thromboxane A2/prostaglandin endoperoxide receptor blockade combined in one molecule--II. Pharmacological effects in vivo and ex vivo.
    De Clerck F, Beetens J, Van de Water A, Vercammen E, Janssen PA.
    Thromb Haemost; 1989 Feb 28; 61(1):43-9. PubMed ID: 2526385
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Thromboxane synthase inhibitors suppress more effectively the aggregation of thromboxane receptor-desensitized than that of normal platelets: role of adenylylcyclase up-regulation.
    Vezza R, Nenci GG, Gresele P.
    J Pharmacol Exp Ther; 1995 Dec 28; 275(3):1497-505. PubMed ID: 8531121
    [Abstract] [Full Text] [Related]

  • 8. Thromboxane A2/prostaglandin endoperoxide (TXA2/PG-END) receptor binding properties in human platelets of ridogrel, a combined TXA2 synthase inhibitor--TXA2/PG-END receptor antagonist.
    Heylen L, De Clerck F, Somers Y, Leysen JE.
    Blood Coagul Fibrinolysis; 1991 Oct 28; 2(5):617-21. PubMed ID: 1838285
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Differential effects of thromboxane A2 synthase inhibition, singly or combined with thromboxane A2/prostaglandin endoperoxide receptor antagonism, on occlusive thrombosis elicited by endothelial cell injury or by deep vascular damage in canine coronary arteries.
    Vandeplassche G, Hemans C, Van de Water A, Xhonneux R, Wouters L, Van Ammel K, De Clerck F.
    Circ Res; 1991 Aug 28; 69(2):313-24. PubMed ID: 1830517
    [Abstract] [Full Text] [Related]

  • 12. R 68 070: thromboxane A2 synthetase inhibition and thromboxane A2/prostaglandin endoperoxide receptor blockade, combined in one molecule.
    De Clerck F, Beetens J, de Chaffoy de Courcelles D, Vercammen E, Freyne E, Janssen PA.
    Prog Clin Biol Res; 1989 Aug 28; 301():567-72. PubMed ID: 2529556
    [No Abstract] [Full Text] [Related]

  • 13. ZD9583, an orally effective thromboxane A2 synthase inhibitor and receptor antagonist with a sustained duration of action in rat and dog.
    Brownlie RP, Brownrigg NJ, Butcher HM, Garcia R, Jessup R, Lee VJ, Tunstall S, Wayne MG.
    J Pharm Pharmacol; 1997 Feb 28; 49(2):187-94. PubMed ID: 9055193
    [Abstract] [Full Text] [Related]

  • 14. Ridogrel, a combined thromboxane synthase inhibitor and receptor blocker, decreases elevated plasma beta-thromboglobulin levels in patients with documented peripheral arterial disease.
    Hoet B, Arnout J, Van Geet C, Deckmyn H, Verhaeghe R, Vermylen J.
    Thromb Haemost; 1990 Aug 13; 64(1):87-90. PubMed ID: 2148849
    [Abstract] [Full Text] [Related]

  • 15. Biosynthesis and pharmacological modulation of thromboxane in humans.
    Patrono C.
    Circulation; 1990 Jan 13; 81(1 Suppl):I12-5; discussion I22-3. PubMed ID: 2136814
    [Abstract] [Full Text] [Related]

  • 16. Improvement of renal function with a selective thromboxane A2 synthetase inhibitor, DP-1904, in lupus nephritis.
    Yoshida T, Kameda H, Ichikawa Y, Tojo T, Homma M.
    J Rheumatol; 1996 Oct 13; 23(10):1719-24. PubMed ID: 8895147
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Influence of selective thromboxane synthetase blocker CGS-13080 on thromboxane and prostacyclin biosynthesis in whole blood: evidence for synthesis of prostacyclin by leukocytes from platelet-derived endoperoxides.
    Mehta J, Mehta P, Lawson DL, Ostrowski N, Brigmon L.
    J Lab Clin Med; 1985 Sep 13; 106(3):246-52. PubMed ID: 3928780
    [Abstract] [Full Text] [Related]

  • 20. Endogenous prostaglandin endoperoxides may alter infarct size in the presence of thromboxane synthase inhibition: studies in a rabbit model of coronary artery occlusion-reperfusion.
    Golino P, Ambrosio G, Villari B, Ragni M, Focaccio A, Pace L, de Clerk F, Condorelli M, Chiariello M.
    J Am Coll Cardiol; 1993 Feb 13; 21(2):493-501. PubMed ID: 8426016
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.